Unit Trusts

UIT

ARK Genomic Healthcare and Biotech Portfolio, 3Q 2015



Distributions

Income distributions will vary with changes in dividends or interest received on the underlying securities and with changes in the trust's fees and expenses. Principal distributions will be made only when the trust receives principal cash and will therefore vary. Both income and principal distributions may be affected by the sale of securities in the portfolio. See the prospectus for a more detailed description of the factors which could affect income and principal distributions.

This page contains historical pricing or historical distributions information for the unit investment trust listed above. It should not be used for federal or state tax purposes, please contact your financial advisor for tax information.

Risk Considerations
There is no assurance that a unit investment trust will achieve its investment objective. An investment in this unit investment trust is subject to market risk, which is the possibility that the market values of securities owned by the trust will decline and that the value of trust units may therefore be less than what you paid for them. This trust is unmanaged. You can lose money investing in this trust.
 
Common stocks do not assure dividend payments. Dividends are paid only when declared by an issuer’s board of directors and the amount of any issuer’s dividend may vary from time to time.0
 
A portfolio concentrated in a single market sector may present more risk than a portfolio broadly diversified over several sectors.
 
This trust is concentrated in the healthcare sector. There are certain risks specific to the healthcare companies such as governmental regulation and the risk that a product may never come to pass.
 
This trust is concentrated in securities of biotechnology companies. Biotechnology companies are subject to government regulation and their valuation can often be based on the potential or actual performance of a limited number of products and can be greatly affected if such products proves to be unsafe, ineffective, or unprofitable.
 
The trust invests in the securities of pharmaceutical companies. Companies in the pharmaceutical industry can be significantly affected by government approval of products and services, government regulation and reimbursement rates, product liability claims, patent expirations and protection and intense competition.
 
Investing in foreign securities involves certain risks not typically associated with investing solely in the United States. This may magnify volatility due to changes in foreign exchange rates, the political and economic uncertainties in foreign countries, U.S. or foreign tax treatment, and the potential lack of liquidity, government supervision and regulation.
 
Stocks of small and mid-cap companies are often more volatile than those of larger companies as a result of several factors such as limited trading volumes, products or financial resources, management inexperience and less publicly available information.
 
Although this trust’s life is approximately 15 months, this strategy should be considered as part of a long-term investment strategy and investors should consider their ability to pursue investing in successive portfolios at the applicable sales charge, if available. There may be tax consequences associated with an investment from one series to the next unless units are purchased in an IRA or other qualified tax-deferred account. Investors should consult their tax advisor or attorney to determine tax consequences associated with an investment from one portfolio to the next.
 
NOT FDIC INSURED - NOT BANK GUARANTEED - MAY LOSE VALUE
 
Incapital Unit Trust, Series 102, is a unit investment trust that consists of the ARK Genomic, Healthcare and Biotech Portfolio, 3Q 2015. Nuveen Securities, LLC serves as the Trust’s sponsor and Nuveen Fund Advisors, LLC serves as the Trust’s evaluator and supervisor.
 
ARK Investment Management (“ARK”) provides the Trust with portfolio consulting services. ARK Investment Management is not affiliated with Nuveen, LLC. The Trust is distributed by Nuveen Securities, LLC, a subsidiary of Nuveen, LLC. All marketing materials have been prepared by Nuveen.


Trust Summary

Trust NameARK Genomic Healthcare and Biotech Portfolio, 3Q 2015
Series Name3Q 2015
Trust SymbolAHB3Q15
Nasdaq SymbolINAHBX
Trust StatusTerminated
Initial Offer Date09/22/2015
Termination Date12/21/2016
First Income Record Date12/10/2015
Distibution FrequencySemi-annually
Tax StructureRIC
Liquidation Price1$9.8338
Cash CUSIP45331B100
Reinvest CUSIP45331B118
Fee Cash CUSIP45331B126
Fee Reinvest CUSIP45331B134

1. Represents the value per unit that a unitholder would receive if the unitholder redeemed or sold units. This price is equal to the net asset value per unit plus any remaining organization costs and creation & development fee. This price reflects any remaining non-contingent deferred sales charges payable in connection with a liquidation of units.

Not registered?

Register for access to investment team commentary, detailed portfolio information, and other advisor resources. For instant access, register now.

Your Contacts

Our goal is to deliver lasting value to our clients. For assistance, please call or email our advisor service team or contact your personal Nuveen Service Team.

Log in to nuveen.com to access your personal Nuveen Service Team.

Financial Advisors

800-752-8700
Email

Registered Investment Advisors

800-558-4487

Account Access

For more information on Mutual Fund Vision, FAN Mail, or accessing client accounts, please visit our advisor account access page.

Advisor Access

Investor Access